<DOC>
	<DOC>NCT02344004</DOC>
	<brief_summary>A study to evaluate the effectiveness of Liposomal Amikacin for Inhalation (LAI) when added to multi-drug regimen in subjects with Nontuberculous Mycobacterial (NTM) lung infection caused by Mycobacterium Avium Complex (MAC).</brief_summary>
	<brief_title>Study to Evaluate Efficacy of LAI When Added to Multi-drug Regimen Compared to Multi-drug Regimen Alone</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Mycobacterium Infections</mesh_term>
	<mesh_term>Mycobacterium Infections, Nontuberculous</mesh_term>
	<mesh_term>Amikacin</mesh_term>
	<criteria>1. Be continually positive for MAC on sputum culture while adhering to a multidrug treatment regimen for a minimum duration of 6 months which is either ongoing or was completed no more than 12 months before screening 2. Be diagnosed with MAC NTM lung infection with evidence of nodular bronchiectasis and/or fibrocavitary disease by chest CT 3. Be willing to adhere to multidrug treatment regimen during the course of the study 1. Patients with cystic fibrosis 2. Positive pregnancy test or lactation at screening. All women of child bearing potential will be tested. Women not of childbearing potential are defined as postmenopausal (i.e., amenorrheic for at least 1 year), or surgically or naturally sterile. 3. Active pulmonary tuberculosis requiring treatment at screening 4. History of lung transplantation 5. Prior exposure to LAI (including clinical study).</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>